Complement Dependent Cytotoxicity in Chronic Lymphocytic Leukemia: Ofatumumab Enhances Alemtuzumab Complement Dependent Cytotoxicity and Reveals Cells Resistant to Activated Complement
Leukemia and Lymphoma - United Kingdom
doi 10.3109/10428194.2012.681657
Full Text
Open PDFAbstract
Available in full text
Date
May 21, 2012
Authors
Publisher
Informa UK Limited